<DOC>
	<DOCNO>NCT02103439</DOCNO>
	<brief_summary>The purpose study demonstrate noninferiority Algeron combination ribavirin compare PegIntron combination ribavirin treatment chronic hepatitis C Human Immunodeficiency Virus-1 infect patient</brief_summary>
	<brief_title>An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety Efficacy Algeron ( Cepeginterferon Alfa-2b ) PegIntron ( Peginterferon Alfa-2b ) Combination With Ribavirin Combined Treatment Chronic Hepatitis C Human Immunodeficiency Virus-1 Infected Patients</brief_title>
	<detailed_description>The course treatment group shall 12 week , efficacy analysis , i.e . rate rapid ( 4th week ) early ( 12th week ) virologic response base polymerase chain reaction data . For patient treatment failure 12th week antiviral therapy shall discontinue . All patient require anti-viral treatment receive combination treatment Algeron / PegIntron ribavirin another 36 week . Sustained virologic response assess 24 week last dose study treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Signed Informed Consent Form . Chronic hepatitis C ( genotypes 1а , 1b , 2 , 3 , 4 ) confirm positive result hepatitis C virus ribonucleic acid &gt; 6 month screen visit accompany increase alanine aminotransferase ( ALT ) level &gt; 6 month screen visit . Confirmed Human Immunodeficiency Virus1 infection base enzymelinked immunosorbent assay immune blot result . Clinically sustain phase Human Immunodeficiency Virus1 infection absence active opportunistic Human Immunodeficiency Virusassociated diseases least 30 calendar day inclusion study . Level CD4+lymphocytes less 500 cells/mm3 patient require highly active antiretroviral therapy assign antiretroviral therapy study period . For patient receive sustain highly active antiretroviral therapy le 12 week plan continue comply treatment regimen follow 24 week , level CD4+lymphocytes ≥300 cells/mm3 , Human Immunodeficiency Virus ribonucleic acid ≤50 copies/ml . Men woman age 18 70 inclusively . Body mass index range 18 30 kg/m2 inclusively . Preserved proteinsynthetizing liver function ( International Normalized Ratio &lt; 1.7 , albumin &gt; 35 g/l ) . Absence sign hepatic encephalopathy ascites accord clinical examination ultrasound examination . Patients preserve childbearing potential partner agree use barrier method contraception whole period therapy 7 month treatment completion . Documentary confirm result liver elastography ( fibroscan ) last year enrollment study patient agreement undergo examination screening . Intolerance alfainterferons , ribavirin component test drug product base medical history . Presence hepatitis B , A , E marker . Presence documentary confirm clinically significant concurrent liver disease ( alcoholic liver cirrhosis , druginduced liver cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , biliary cirrhosis etc. ) . Past history Hepatitis C Virus treatment interferon alfa pegylated interferon alfa . For patient receive sustain highly active antiretroviral therapy presence nevirapine , stavudine , zidovudine , didanosine treatment regimen . Use injectable noninjectable interferon alfa/ interferon inducer indication ( except hepatitis C ) , radiotherapy , cytotoxic chemotherapy one month prior inclusion study . Cholestic hepatitis ( level direct bilirubin , alkaline phosphatase , gamma glutamyltransferase , exceed upper normal limit &gt; 5 time ) . Decompensated liver cirrhosis confirm result laboratory analysis ( ChildPugh class B , C ) ultrasound examination . Any documentary confirm autoimmune disease ( Crohn 's disease , ulcerative colitis , systemic lupus erythematosus , idiopathic thrombocytopenic purpura , scleroderma , autoimmune hemolytic anemia , severe psoriasis ) . Deviations hematologic ( hemoglobin less low normal limit ; neutrophil &lt; 1.5 x 10^9/l ; thrombocyte &lt; 90 x 10^9/ l ) biochemical ( creatinine level &gt; 1.5 time high upper normal limit , ALT &gt; 10 time high upper normal limit ) parameter . Documentary confirm diagnosis hemoglobinopathy ( example , thalassemia , sicklecell anemia ) . Severe depression , schizophrenia , mental disorder accord investigator contraindication antiviral treatment . Epilepsy and/or central nervous system disorder . Disorder thyroid function ( level thyroid stimulate hormone normal range ) . Documentary confirm suspected hepatocellular carcinoma base result alfafetoprotein ( AFP ) assay ≥ upper normal limit . Antinuclear antibody ( ANA ) titer measure screen less 1:640 documentary confirm sign autoimmune hepatitis base result biopsy . Documentary confirm malignant neoplasm . Documentary confirm lung disease associate respiratory failure . Treatment Human Immunodeficiency Virus1 immunotherapeutic vaccine within 90 day prior screen . Necessity assignment antimycobacterial therapy . Pregnancy , lactation period . Documentary confirm retinopathy ( example , cytomegalovirus retinitis , macular degeneration ) . Severe concurrent disease ( example , severe arterial hypertension , sever coronary heart disease , heart failure , decompensated diabetes mellitus ) contraindication antiviral therapy accord investigator opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cepeginterferon alfa</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Treatment</keyword>
</DOC>